查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1318977

阵发性夜间血尿症治疗市场：透过诊断测试、治疗 - 全球预测 2023-2030

Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test, Treatment - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球阵发性夜间血尿症治疗市场将大幅成长，达315892万美元，年复合成长率为10.86%，2030年将达651083万美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球阵发性夜间血尿症治疗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.阵发性夜间血尿症治疗的全球市场规模与预测是多少？

2.在预测期内，COVID-19对全球阵发性夜间血尿症治疗市场的阻碍因素与影响有哪些？

3.预测期内，全球阵发性夜间血尿症治疗市场需要投资哪些产品/细分市场/应用/领域？

4.全球阵发性夜间血尿症治疗市场的竞争策略为何？

5.全球阵发性夜间血尿症治疗市场的技术趋势与法律规范是什么？

6.全球阵发性夜间血尿症治疗市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入全球阵发性夜间血尿症治疗市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 增加新治疗方法的采用
      • 老年人口的增加和生物製剂的出现
      • 血液和骨髓相关疾病呈上升趋势
    • 抑制因素
      • 治疗费用高昂
    • 机会
      • 干细胞研究进展
      • PNH 治疗研发投资增加
    • 任务
      • 现有治疗方法的不良副作用
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章阵发性夜间血尿症诊断测试​​治疗市场

  • 骨髓检查
  • 完成血球计数测试
  • 流式细胞仪
  • 乳酸脱氢酵素测试
  • 尿液检查含铁血黄素

第7章阵发性夜间血尿症治疗市场（依治疗）

  • 输血
  • 剂量
  • 干细胞移植

第8章美洲阵发性夜间血尿症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第9章亚太阵发性夜间血尿症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲阵发性夜间血尿症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第11章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-036C5CF3B550

The Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market is forecasted to grow significantly, with a projected USD 3,158.92 million in 2023 at a CAGR of 10.86% and expected to reach a staggering USD 6,510.83 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Diagnostic Test, market is studied across Bone Marrow Examination, Complete Blood Count Test, Flow Cytometry, Lactate Dehydrogenase Test, and Urine Test for Hemosiderin. The Bone Marrow Examination is projected to witness significant market share during forecast period.

Based on Treatment, market is studied across Blood Transfusion, Medication, and Stem Cell Transplant. The Medication is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?

4. What is the competitive strategic window for opportunities in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?

5. What are the technology trends and regulatory frameworks in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?

6. What is the market share of the leading vendors in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?

7. What modes and strategic moves are considered suitable for entering the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Diagnostic Test, 2022 vs 2030
  • 4.3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment, 2022 vs 2030
  • 4.4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of novel therapeutics
      • 5.1.1.2. Rising geriatric population and the emergence of biologics
      • 5.1.1.3. Growing number of blood and bone marrow related disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with medical treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing development in stem cell research
      • 5.1.3.2. Rising investment in research & development of PNH treatment drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse side effects with existing treatments
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Diagnostic Test

  • 6.1. Introduction
  • 6.2. Bone Marrow Examination
  • 6.3. Complete Blood Count Test
  • 6.4. Flow Cytometry
  • 6.5. Lactate Dehydrogenase Test
  • 6.6. Urine Test for Hemosiderin

7. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Blood Transfusion
  • 7.3. Medication
  • 7.4. Stem Cell Transplant

8. Americas Paroxysmal Nocturnal Hemoglobinuria Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2022 VS 2030
  • FIGURE 3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2022 VS 2030 (%)
  • FIGURE 5. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
  • FIGURE 6. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET DYNAMICS
  • FIGURE 8. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 5. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BONE MARROW EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLETE BLOOD COUNT TEST , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LACTATE DEHYDROGENASE TEST , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY URINE TEST FOR HEMOSIDERIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 101. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 102. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET LICENSE & PRICING